It does seem a little odd to suggest that pharma, and all its offshoots, is finally ‘exploding on to the scene’. But it is.

Cartesian Therapeutics has secured an agreement from the US Food and Drug Administration (FDA) under the Special Protocol ...

The US Food and Drug Administration (FDA) has approved a new dosing regimen for LEQEMBI, a treatment for early Alzheimer’s disease, according to Eisai and Biogen Inc. The maintenance dosing will now ...

Vedanta Biosciences has published additional results from its Phase 2 CONSORTIUM study for VE303, a potential first-in-class ...

Alligator Bioscience has announced positive outcomes from indirect treatment comparison studies, showing that mitazalimab ...

Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for ...

Tris Pharma, Inc. has announced positive results from its ALLEVIATE-1 phase 3 clinical trial evaluating cebranopadol for ...

This initiative, funded by the Innovative Health Initiative Joint Undertaking (IHI JU) with over EUR 38 million, aims to ...

AstraZeneca has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for ...

Datapharm has announced its expansion into the United States through a new partnership with phactMI. The collaboration aims ...

The UK experienced a notable increase in advanced therapy clinical trials in 2024, reaching 187 ongoing trials. This marks a ...

The European Commission (EC) has approved the marketing authorisation for LAZCLUZE (lazertinib) in combination with RYBREVANT ...